Press Releases

 ENB-0040, A Bone Targeted Enzyme Replacement Therapy, Shows Promise in Children with HypophosphatasiaJune 21, 2010Enobia Presents Results from Hypophosphatasia Impact Patient SurveyMarch 29, 2010Enobia Expands Clinical Program for ENB-0040, a Bone-targeted Enzyme Replacement Therapy for HypophosphatasiaNovember 02, 2009Enobia Announces Positive Clinical Results with ENB-0040, a Bone Targeted Enzyme Replacement Therapy for HypophosphatasiaSeptember 14, 2009Enobia Raises US$50M from Current Investors in Series C FinancingAugust 10, 2009Enobia Announces Positive Interim Clinical Results with ENB-0040June 11, 2009Enobia Pharma's ENB-0040 receives FDA fast track designationMay 19, 2009Enobia completes target enrollment in clinical trial for infantile HypophosphatasiaMarch 03, 2009Enobia initiates infantile enzyme replacement trial for rare bone diseaseDecember 01, 2008Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management TeamSeptember 22, 2008Enobia Pharma receives FDA orphan drug designation for Hypophosphatasia product candidate ENB-0040September 19, 2008Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in MiceSeptember 15, 2008Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat HypophosphatasiaAugust 20, 2008Enobia Pharma Raises $40.1 Million Series B FinancingSeptember 10, 2007Laureate Pharma Announces Agreement with Enobia Pharma, Inc.July 25, 2007Enobia Pharma Announces the Appointment of Dr. Hal Landy as VP Medical Affairs, Chief Medical OfficerJune 18, 2007Enobia Pharma Announces the Appointment of Dr. Robert Heft as Chief Executive Officer November 24, 2005

Press Release Archive:  2010 | 2009 | 2008 | 2007 | 2005 | View All